Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200, a Transforming Growth Factor B Inhibitor, in Diffuse Cutaneous Systemic Sclerosis

Site Image

Study Overview

This study is being done to learn more about the safety of the study drug, AVID200, and to find out more about the effects of different study drug doses in people with scleroderma.  AVID200 is referred to as an investigational drug because it is in the early stages of development and has not been approved by the U.S. Food and Drug Administration, which means that it is not available to be prescribed or sold.  The study drug is given intravenously (in the vein) over 1 hour.  Study drug is given once every 2 weeks for a total of 3 doses.

  • Study Identifier: 832173

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email